{"entity":{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","aka":[],"tldr":"Led PALETTE, the trial that made pazopanib the first targeted drug for soft-tissue sarcoma.","summary":"Winette van der Graaf was principal investigator of PALETTE, the EORTC trial showing pazopanib improves progression-free survival in pretreated non-adipocytic soft-tissue sarcoma, leading to its approval as the first targeted therapy in the disease. She chaired the EORTC Soft Tissue and Bone Sarcoma Group and leads adolescent and young adult cancer research in the Netherlands.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20der%20Graaf%20WT%5BAuthor%5D%20sarcoma%20pazopanib"}],"tags":["sarcoma","eortc","aya"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["kinase-inhibitors","antiangiogenic"],"targets":["vegf"],"drugs":[],"companies":[],"institutions":["nki","erasmus-mc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["esmo-open"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Netherlands Cancer Institute and Erasmus MC","institutionId":"nki","specialisms":["Soft-tissue sarcoma","Adolescent and young adult oncology","Targeted therapy","EORTC trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20der%20Graaf%20WT%5BAuthor%5D%20sarcoma%20pazopanib"}],"papers":[{"title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE)","journal":"Lancet","year":2012,"doi":"10.1016/S0140-6736(12)60651-5"},{"title":"Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)","journal":"ESMO Open","year":2021,"doi":"10.1016/j.esmoop.2021.100096"}],"orcid":"0000-0001-7549-3338"},"route":"/people/winette-van-der-graaf/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"institution":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"journal":[{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/"}]}}